BRCA2 and prostate carcinoma: Despite these numerous limitations, we believe that the differences observed in survival of the BRCA1 and BRCA2 carriers (Figures 1 and 2) can be attributed to the adverse effect of the BRCA2 mutation on prostate cancer survival.